A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Aminopterin
  • Antineoplastic Combined Chemotherapy Protocols
  • Folic Acid Antagonists
  • Neoplasms
  • Paclitaxel
  • Taxoids

abstract

  • Pralatrexate (120 mg/m(2)) plus docetaxel (35 mg/m(2)) plus vitamin supplementation is well tolerated with signs of efficacy against non-small-cell lung cancer that merit phase 2 testing.

publication date

  • May 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-06-1754

PubMed ID

  • 17473201

Additional Document Info

start page

  • 2692

end page

  • 8

volume

  • 13

number

  • 9